Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

PAVmed Reports Preliminary Third-Quarter 2026 Results and Medicare EsoGuard Coverage

None

PAVmed (PAVM) reported preliminary third-quarter 2026 revenue of $41,000 and a net loss of $13.0 million. Operating expenses were approximately $6.8 million for the quarter ended September 30, including $1.0 million of stock-based compensation expense.

The company said Lucid Diagnostics began receiving Medicare payments for EsoGuard in October, while Veris Health completed design freeze for its implantable physiological monitor and began a 90-day GLP animal study.

  • Lucid performed 2,871 EsoGuard tests and recognized $1.2 million in third-quarter revenue.
  • October EsoGuard test volume exceeded 1,800 tests, a record monthly level.
  • PAVmed reported $8.9 million in cash and cash equivalents as of September 30, including $5.3 million of restricted cash.
  • Veris expects an early 2027 FDA 510(k) submission for its implantable monitor.
  • PAVmed held an initial FDA meeting on PortIO and expects an in-person pre-submission meeting in January 2027.
EARLY ACCESS
Receive PAVM Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$PAVM Hedge Fund Activity

We have seen 10 institutional investors add shares of $PAVM stock to their portfolio, and 9 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles